Gilteritinib Relapse Leads to Loss of FLT3-TKD Mutation in Patient With AML
Adam Fisch, MD, PhD, a clinical fellow in molecular genetic pathology at the Brigham’s Women’s Hospital, discusses the key points from a patient case he presented at the 2019 Association for Molecular Pathology Annual Meeting and Expo, in which the patient with acute myeloid leukemia harboring a FLT3-TKD mutation lost the mutation following relapse on gilteritinib.
Adam Fisch, MD, PhD, a clinical fellow in molecular genetic pathology at the Brigham’s Women’s Hospital, discusses the key points from a patient case he presented at the 2019 Association for Molecular Pathology (AMP) Annual Meeting and Expo (AMP 2019), in which the patient with acute myeloid leukemia (AML) harboring aFLT3-TKD mutation lost the mutation following relapse on gilteritinib (Xospata).
The FLT3 tyrosine kinase inhibitor gilteritinib, which wasapproved by the FDA in November of 2018 for adult patients withFLT3-mutant AML, is efficacious in many different patients withFLT3-mutant AML, but the case of the patient losing the mutation upon relapse is unexpected. This kind of event has not been reported much in literature, and there is not a lot of discussion about the disappearance of aFLT3-TKD following relapse on a TKI, Fisch says.
Genetics and Ring Sideroblasts Impact ESA-Refractory Anemia in MDS
September 5th 2024During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case of myelodysplastic syndrome first treated with erythropoiesis-stimulating agent in the second article of a 2-part series.
Read More
Tisa-cel Emerges as Earlier Option in Pediatric Acute Lymphoblastic Leukemia
September 5th 2024The use of CAR T-cell therapy tisagenlecleucel has decreased the need for HSCT in pediatric and young adult patients with relapsed/refractory B-ALL, according to data from a noninterventional study.
Read More
